Correlation Between GT Biopharma and Gemina Laboratories

Can any of the company-specific risk be diversified away by investing in both GT Biopharma and Gemina Laboratories at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GT Biopharma and Gemina Laboratories into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between GT Biopharma and Gemina Laboratories, you can compare the effects of market volatilities on GT Biopharma and Gemina Laboratories and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GT Biopharma with a short position of Gemina Laboratories. Check out your portfolio center. Please also check ongoing floating volatility patterns of GT Biopharma and Gemina Laboratories.

Diversification Opportunities for GT Biopharma and Gemina Laboratories

0.19

Correlation Coefficient

GT Biopharma  Gemina Laboratories

Average diversification

The 3 months correlation between GTBP and Gemina is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding GT Biopharma and Gemina Laboratories in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gemina Laboratories and GT Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GT Biopharma are associated (or correlated) with Gemina Laboratories. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gemina Laboratories has no effect on the direction of GT Biopharma i.e., GT Biopharma and Gemina Laboratories go up and down completely randomly.

Pair Corralation between GT Biopharma and Gemina Laboratories

Given the investment horizon of 90 days GT Biopharma is expected to generate 2.19 times less return on investment than Gemina Laboratories. But when comparing it to its historical volatility, GT Biopharma is 1.04 times less risky than Gemina Laboratories. It trades about 0.03 of its potential returns per unit of risk. Gemina Laboratories is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  40.00  in Gemina Laboratories on October 4, 2024 and sell it today you would earn a total of  15.00  from holding Gemina Laboratories or generate 37.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

GT Biopharma  vs.  Gemina Laboratories

GT Biopharma

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in GT Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, GT Biopharma reported solid returns over the last few months and may actually be approaching a breakup point.

Gemina Laboratories

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Gemina Laboratories are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating fundamental drivers, Gemina Laboratories reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with GT Biopharma and Gemina Laboratories

The main advantage of trading using opposite GT Biopharma and Gemina Laboratories positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GT Biopharma position performs unexpectedly, Gemina Laboratories can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gemina Laboratories will offset losses from the drop in Gemina Laboratories' long position.

The idea behind GT Biopharma and Gemina Laboratories pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.